SCHEMBL2297867

SCHEMBL2297867

O=C(O)Nc1nc2ccc(C(=O)c3ccccc3C(=O)Nc3cc(Br)ccc3F)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.54
▸ BRAF P15056 5/20 0.54
▸ CYP2C9 P11712 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ABL1 P00519 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ KDR P35968 3/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ ABCC4 O15439 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299292 0.90 RAF1 (0.55) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2297946 0.90 RAF1 (0.57) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2300130 0.90 RAF1 (0.57) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2358832 0.89 RAF1 (0.54) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2357346 0.85 RAF1 (0.54) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2299039 0.85 RAF1 (0.54) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2357595 0.85 RAF1 (0.56) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL1467948 0.84 MAPT (0.46) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2356348 0.84 RAF1 (0.59) RAF1BRAFCYP2C9MAPTCYP2C19
SCHEMBL2299028 0.82 RAF1 (0.57) RAF1BRAFCYP2C9MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback